Vital Signs - Embryonic Stem Cells: Moving Ahead in 2009


USD 1,500.00

* Required Fields

USD 1,500.00


Be the first to review this product

This issue of Vital Signs, released on September 28, 2009, provides a strategic overview of recent trends and activities in embryonic stem cell therapy research. Additionally, a company spotlight is provided for KYTHERA Biopharmaceuticals, Inc., a biopharmaceutical company focused on developing aesthetic medications. Reimbursement and regulatory news from the FDA is also provided for the week of September 14, 2009.

Table of Contents

Vital Signs - Embryonic Stem Cells: Moving Ahead in 2009Vital Signs: 28 September 2009This week's issue:

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.